STOCK TITAN
  1. Home
  2. News
  3. RVMD

Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Goldman Sachs 44th Annual Global Healthcare Conference and in Barclays’ ongoing series of virtual lunchtime fireside chats.

Details of the company’s participation are as follows:

  • Goldman Sachs 44th Annual Global Healthcare Conference
    Conference Dates: June 12-15, 2023
    Fireside Chat Time/Date: 11:40 a.m. Eastern on Wednesday, June 14, 2023
    Location: Dana Point, California; webcast available
  • Barclays Virtual Fireside Chat Series
    Fireside Chat Time/Date: 12:00 p.m. Eastern on Thursday, June 15, 2023
    Location: Virtual; webcast available

To access the live webcasts of the Goldman Sachs and Barclays fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).


Stock RVMD logo
Revolution Medicines Inc

NASDAQ:RVMD

RVMD Rankings

#1109 Ranked by Market Cap
#2552 Ranked by Stock Gains
N/A Ranked by Dividends

RVMD Latest News

Apr 9, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Apr 8, 2024
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Apr 4, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
Mar 28, 2024
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
Feb 26, 2024
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

RVMD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Redwood City

About RVMD

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.